Innovent says Phase 3 RESTORE-3 trial shows SYCUME meets primary endpoint in inactive thyroid eye disease

• Innovent reported its Phase 3 RESTORE-3 trial met the primary endpoint for SYCUME in inactive thyroid eye disease.
• The study showed a meaningful reduction in eye bulging versus placebo, supporting a non-surgical treatment option for chronic patients.
• Safety and tolerability were described as favorable, with no new safety signals flagged during blinded treatment and follow-up.
• Complete results have not yet been presented; the dataset will be shared at future medical meetings or in peer-reviewed journals.
• The readout strengthens SYCUME’s positioning in China’s thyroid eye disease market, where it is already listed on the national reimbursement drug list.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610082000PR_NEWS_USPR_____CN66959) on October 09, 2026, and is solely responsible for the information contained therein.